Horse tranquilliser trial is awarded $750,000 grant for Parkinson’s research

News

Author: Simge Eva DoganPublished: 26 July 2018

Prep: Cook: Serves:

Researchers at the University of Arizona College of Medicine, Tucson, US, will be trialling ketamine – a recreational drug previously used to medicate people with depression – as a treatment for Parkinson’s.

The research – led by Dr Scott Sherman – is being supported with a three-year grant of $750,000 from the Arizona Biomedical Research Commission.

The initial clinical trial will test the effect of ketamine for treating dyskinesia in 10 patients. In addition, the researchers will carry out a separate rodent study to examine how the drug affects the brain.

Dr Scott Sherman, a neurologist at the University of Arizona College of Medicine, said: “Ketamine has been long overlooked. Now it could prove very useful for Parkinson’s patients.”

For information on the latest Parkinson’s research please visit the European Parkinson’s Disease Association website.

For more information on this article click here.

Last Month

Next Month

Go Back

Share this story

Comments

Episodes

Podcast: Deciding to have DBS surgery

Two guests discuss deep brain stimulation for Parkinson’s disease

Is your Parkinson’s making you tired?

The man who walked 80km in one day for Parkinson’s

Clint Bauld walked for 24 hours in aid of Parkinson’s

Study suggests why neurons die in Parkinson’s disease

Researchers at the University of Córdoba, Spain, have discovered how a certain protein may be linked to death of dopamine-producing neurons associated with Parkinson’s. Using animal models of the condition to conduct their study, the team focused on the protein DJ-1 – whose link to Parkinson’s has previously been established, though its exact function was uncertain. The researchers compared neurons in the brains of mice that possessed the gene expressing DJ-1 with those that did not. The findings revealed that dysfunction or absence of the gene expressing the DJ-1 protein could trigger the ‘cell cycle’ (the process by which cells divide), which should not occur under normal conditions. Because neurons lack the capacity to divide, this causes them die – leading to the onset of symptoms linked with Parkinson’s. It is hoped that uncovering these details about the relationship between DJ-1’s absence and Parkinson’s may lead to the development of…

Researchers have finally identified brain cells linked to Parkinson’s disease

For decades, scientists have known that Parkinson’s is associated with the death of dopamine-producing cells in the brain. Now, researchers from the Broad Institute of MIT and Harvard, US, have discovered the specific subtype of brain cells that die in Parkinson’s disease. Using a technique called single-cell RNA signalling, which enables the individual analysis of cells within a tissue for activity and protein production, researchers identified 10 subtypes of dopamine-producing cells within the donated brains of people who died from causes unrelated to Parkinson’s. The team carried out the same investigation on people who had died with Parkinson’s or a condition with similar symptoms called Lewy body dementia. They discovered that only one subtype of the cells had reduced in number – which suggests many of these cells had died while the people were living. It is hoped that the findings could lead to better understanding of Parkinson’s causes and…

Tiny DBS implant shows potential to advance Parkinson’s disease treatment

In an innovative trial by North Bristol NHS Trust, UK, surgeons have succeeded in implanting a tiny deep brain stimulation (DBS) device into a person’s skull. Their aim? To address symptoms of Parkinson’s. Designed with a tiny battery system that is inserted into the skull, the DBS device delivers electric impulses to targeted areas of the brain through electric probes. In doing so, it works to address abnormal brain cell activity associated with Parkinson’s – and may help to ease symptoms. One of around 25 patients selected for the year-long trial has described the device’s impact as “amazing”. Commenting on the results of the trial so far, consultant neurologist Dr Alan Whone of North Bristol NHS Trust said: “We are hopeful that if these findings hold up, we will have a significant technical advance by which to improve Parkinson’s care across the world.”

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Phone
This field is for validation purposes and should be left unchanged.

Horse tranquilliser trial is awarded $750,000 grant for Parkinson’s research

News

Author: Simge Eva DoganPublished: 26 July 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

sponsored article

Episodes

Podcast: Deciding to have DBS surgery

Resources & Tools

Is your Parkinson’s making you tired?

Interviews

The man who walked 80km in one day for Parkinson’s

Study suggests why neurons die in Parkinson’s disease

Researchers have finally identified brain cells linked to Parkinson’s disease

Tiny DBS implant shows potential to advance Parkinson’s disease treatment

{title}

Subscribe

Horse tranquilliser trial is awarded $750,000 grant for Parkinson’s research

News

Author: Simge Eva DoganPublished: 26 July 2018

Last Month

Next Month

Share this story

Comments

Related articles

sponsored article

Episodes

Podcast: Deciding to have DBS surgery

Resources & Tools

Is your Parkinson’s making you tired?

Interviews

The man who walked 80km in one day for Parkinson’s

Study suggests why neurons die in Parkinson’s disease

Researchers have finally identified brain cells linked to Parkinson’s disease

Tiny DBS implant shows potential to advance Parkinson’s disease treatment

{title}

Subscribe

Sign in